These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 26608671)
41. Absence of Drug-Drug Interactions Between Luseogliflozin, a Sodium-Glucose Co-transporter-2 Inhibitor, and Various Oral Antidiabetic Drugs in Healthy Japanese Males. Sasaki T; Seino Y; Fukatsu A; Ubukata M; Sakai S; Samukawa Y Adv Ther; 2015 May; 32(5):404-17. PubMed ID: 25975816 [TBL] [Abstract][Full Text] [Related]
42. Effects of hydrochlorothiazide on the pharmacokinetics, pharmacodynamics, and tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants. Devineni D; Vaccaro N; Polidori D; Rusch S; Wajs E Clin Ther; 2014 May; 36(5):698-710. PubMed ID: 24726680 [TBL] [Abstract][Full Text] [Related]
43. Bioequivalence of sitagliptin/metformin fixed-dose combination tablets and concomitant administration of sitagliptin and metformin in healthy adult subjects: a randomized, open-label, crossover study. Migoya EM; Miller JL; Gutierrez M; Zheng W; Johnson-Levonas AO; Liu Q; Matthews CZ; Wagner JA; Gottesdiener KM Clin Drug Investig; 2010; 30(12):855-66. PubMed ID: 20923244 [TBL] [Abstract][Full Text] [Related]
44. Pharmacokinetics of Single-dose Ertugliflozin in Patients With Hepatic Impairment. Sahasrabudhe V; Terra SG; Hickman A; Saur D; Raje S; Shi H; Matschke K; Zhou S; Cutler DL Clin Ther; 2018 Oct; 40(10):1701-1710. PubMed ID: 30224193 [TBL] [Abstract][Full Text] [Related]
45. Drug-drug interactions with sodium-glucose cotransporters type 2 (SGLT2) inhibitors, new oral glucose-lowering agents for the management of type 2 diabetes mellitus. Scheen AJ Clin Pharmacokinet; 2014 Apr; 53(4):295-304. PubMed ID: 24420910 [TBL] [Abstract][Full Text] [Related]
46. Pharmacokinetics and bioequivalence evaluation of gliclazide/metformin combination tablet and equivalent doses of gliclazide and metformin in healthy Korean subjects. Cho HY; Yoon H; Lim YC; Lee YB Int J Clin Pharmacol Ther; 2009 Dec; 47(12):770-9. PubMed ID: 19954716 [TBL] [Abstract][Full Text] [Related]
48. Pharmacokinetics and pharmacodynamics of rongliflozin, a novel selective inhibitor of sodium-glucose co-transporter-2, in people with type 2 diabetes mellitus. Zhang H; Zhu X; Li X; Chen H; Wu M; Li C; Liu J; Liu C; Zhang Y; Ding Y Diabetes Obes Metab; 2020 Feb; 22(2):191-202. PubMed ID: 31588657 [TBL] [Abstract][Full Text] [Related]
49. Pharmacokinetic interaction between rosuvastatin and metformin in healthy Korean male volunteers: a randomized, open-label, 3-period, crossover, multiple-dose study. Lee D; Roh H; Son H; Jang SB; Lee S; Nam SY; Park K Clin Ther; 2014 Aug; 36(8):1171-81. PubMed ID: 24976448 [TBL] [Abstract][Full Text] [Related]
50. SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO. Lingvay I Endocr Pract; 2017 Jul; 23(7):831-840. PubMed ID: 28332871 [TBL] [Abstract][Full Text] [Related]
51. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus. Plosker GL; Figgitt DP Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124 [TBL] [Abstract][Full Text] [Related]
52. Lack of clinically relevant drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and verapamil, ramipril, or digoxin in healthy volunteers. Macha S; Sennewald R; Rose P; Schoene K; Pinnetti S; Woerle HJ; Broedl UC Clin Ther; 2013 Mar; 35(3):226-35. PubMed ID: 23497760 [TBL] [Abstract][Full Text] [Related]
53. Mechanism-Based Pharmacokinetic-Pharmacodynamic Modeling of Luseogliflozin, a Sodium Glucose Co-transporter 2 Inhibitor, in Japanese Patients with Type 2 Diabetes Mellitus. Samukawa Y; Mutoh M; Chen S; Mizui N Biol Pharm Bull; 2017; 40(8):1207-1218. PubMed ID: 28769002 [TBL] [Abstract][Full Text] [Related]
54. Study of the pharmacokinetic interaction of vildagliptin and metformin in patients with type 2 diabetes. He YL; Sabo R; Picard F; Wang Y; Herron J; Ligueros-Saylan M; Dole WP Curr Med Res Opin; 2009 May; 25(5):1265-72. PubMed ID: 19364302 [TBL] [Abstract][Full Text] [Related]
55. Effects of Child-Pugh B Cirrhosis on Pharmacokinetics of Tofogliflozin, a New Sodium-Glucose Co-Transporter (SGLT2) Inhibitor. Yamada H; Ohira H; Ikegami F; Nakamura K; Takahashi A; Abe K; Inano A; Shimada S; Miyata K; Saito T; Ohba Y; Terao K; Ohnishi A Drug Res (Stuttg); 2020 Sep; 70(9):401-409. PubMed ID: 32707593 [TBL] [Abstract][Full Text] [Related]
56. Assessment of Pharmacodynamic and Pharmacokinetic Interaction of Aqueous Extract of Cassia auriculata L. and Metformin in Rats. Elango H; Ponnusankar S; Sundaram S Pharmacogn Mag; 2015 Oct; 11(Suppl 3):S423-6. PubMed ID: 26929576 [TBL] [Abstract][Full Text] [Related]
58. Single-dose Pharmacokinetics and Pharmacodynamics of Canagliflozin, a Selective Inhibitor of Sodium Glucose Cotransporter 2, in Healthy Indian Participants. Devineni D; Polidori D; Curtin C; Stieltjes H; Tian H; Wajs E Clin Ther; 2016 Jan; 38(1):89-98.e1. PubMed ID: 26687552 [TBL] [Abstract][Full Text] [Related]
59. The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus. Lajara R Expert Opin Pharmacother; 2014 Dec; 15(17):2565-85. PubMed ID: 25316597 [TBL] [Abstract][Full Text] [Related]
60. Pharmacokinetics of a fixed-dose combination of atorvastatin and metformin extended release versus concurrent administration of individual formulations: a randomized, open-label, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study. Kandhwal K; Dey S; Nazarudheen S; Arora R; Reyar S; Thudi NR; Monif T; Singh MK; Rao S Clin Drug Investig; 2011 Dec; 31(12):853-63. PubMed ID: 21919543 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]